| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers R > Headlines for Response Biomedical Corp. > News item |
Response says independent tests point to superior performance for firm's flu test
By Ted A. Knutson
Washington, Jan. 18 - Response Biomedical Corp. announced Wednesday initial evaluations by independent public health organizations demonstrated that the company's rapid RAMP Flu A Test had significantly greater sensitivity than existing point-of-care diagnostic products.
Response now plans to begin multi-center clinical trials of its RAMP Flu A and Flu B Tests during the current flu season.
"The RAMP Flu A Test has consistently demonstrated sensitivity that is of an order of magnitude higher than available rapid tests," said Dr. Paul C. Harris, vice president, research and development, in a news release. "This superior level of sensitivity was also observed in detecting the H5N1 strain of Avian Flu, which provides confidence RAMP will be a clinically valuable diagnostic tool for both human and animal testing."
The company added commercially available rapid tests are limited in their sensitivity, which contributes to 'false negative' results and necessitates confirmatory lab testing. The current confirmatory lab test for influenza relies on cell culture, which takes one to two days to obtain a result. RAMP provides clinically relevant information in about 15 minutes, well within the 48-hour window of opportunity for administering antiviral therapy.
While more than 85% of all flu cases are type A, the company has also recently completed feasibility and begun development of a RAMP Flu B Test.
Vancouver, B.C.-based Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its portable RAMP Platform for clinical and environmental applications.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.